Also in the News: Radium-223 Improves Survival in Men with Metastatic Prostate Cancer
Final data from a trial involving men with castrate-resistant prostate cancer that had spread to the bones showed that radium-223 (Alpharadin) improved overall survival by more than 3 months. Radium-223, part of a class of drugs called alpha-particle emitters, targets bone metastases.
The final results from the ALSYMPCA trial were presented October 28 at the American Society for Radiation Oncology annual meeting
.
Overall survival in the final analysis of the trial was 14.9 months for men who received radium-223 compared with 11.3 months for men who received a placebo, a slight improvement over the findings of an interim analysis presented earlier this year.
Men treated with radium-223 also lived nearly 40 percent longer without having a skeletal-related event, such as a bone fracture or spinal cord compression, or the need for radiation therapy to treat symptomatic bone metastases.
Final data from a trial involving men with castrate-resistant prostate cancer that had spread to the bones showed that radium-223 (Alpharadin) improved overall survival by more than 3 months. Radium-223, part of a class of drugs called alpha-particle emitters, targets bone metastases.
The final results from the ALSYMPCA trial were presented October 28 at the American Society for Radiation Oncology annual meeting
.Overall survival in the final analysis of the trial was 14.9 months for men who received radium-223 compared with 11.3 months for men who received a placebo, a slight improvement over the findings of an interim analysis presented earlier this year.
Men treated with radium-223 also lived nearly 40 percent longer without having a skeletal-related event, such as a bone fracture or spinal cord compression, or the need for radiation therapy to treat symptomatic bone metastases.
.png)
No hay comentarios:
Publicar un comentario